Arvinas, Inc.
ARVN Healthcare Biotechnology
Arvinas, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $262.6 million, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 1,014.7%, EPS grew 410.7%, free cash flow grew 49.8% and total debt fell 40.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ARVN
A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income |
(80.80) | (198.90) | (367.30) | (282.50) | (191.00) | (119.30) | (70.30) | (41.48) | (24.05) | (14.35) |
Depreciation & Amortization |
(3.30) | (10.60) | (8.60) | 15.70 | 15.80 | 5.80 | 2.50 | 0.97 | 0.71 | 0.97 |
Non Cash Items (Other) |
44.00 | 90.80 | 72.50 | 75.90 | 56.30 | 29.80 | 20.10 | 11.82 | 0.24 | (0.47) |
Accounts Receivable Change |
4.70 | (5.70) | 1.00 | 14.00 | (14.00) | (1.00) | 2.80 | 22.22 | (25.00) | (0.58) |
Accounts Payable Change |
(1.70) | (21.20) | 17.30 | 20.20 | 27.90 | 12.80 | 1.50 | 2.00 | (0.97) | 1.20 |
Change in payables and accrued liability |
— | — | — | — | — | — | 3.60 | 0.61 | 1.89 | 0.55 |
Change in other assets and liabilities |
(236.70) | (113.70) | (62.70) | (116.80) | 664.40 | (17.80) | (0.80) | (12.26) | 52.29 | (7.31) |
Operating Cash Flow |
(273.80) | (259.30) | (347.80) | (273.50) | 559.40 | (89.70) | (40.60) | (16.12) | 5.11 | (19.40) |
Capital expenditures |
(1.90) | (1.70) | (2.90) | (6.80) | (4.70) | (6.40) | (6.30) | (2.83) | (1.01) | (0.26) |
Short Term Investments Change (Net) |
409.50 | 36.40 | 206.40 | 249.60 | (1,308.90) | 170.70 | (86.80) | (176.83) | 21.88 | (19.81) |
Other investing activities |
— | — | — | — | — | — | — | — | — | (0.05) |
Investing cash flow |
407.60 | 34.70 | 203.50 | 242.80 | (1,313.60) | 164.30 | (93.10) | (179.67) | 20.87 | (20.11) |
Repayment/Issuance of Debt (Net) |
(0.20) | (0.40) | — | (1.90) | (1.30) | (0.92) | (0.20) | 1.83 | (0.16) | (0.15) |
Equity Repurchase (Common, Net) |
(91.20) | 8.30 | 391.70 | 4.70 | 283.20 | 532.30 | 140.50 | 114.66 | — | — |
Equity Repurchase (Preffered, Net) |
— | — | — | — | — | — | — | 55.00 | — | — |
Other financial activities |
— | — | (17.00) | 83.40 | (4.60) | (27.70) | (0.60) | (3.42) | 0.60 | 0.07 |
Financing cash flow |
(91.40) | 7.90 | 374.70 | 4.70 | 278.60 | 504.60 | 139.70 | 168.06 | (0.16) | (0.15) |
Change in Cash |
42.40 | (216.70) | 230.40 | (26.00) | (475.60) | 579.20 | 6.00 | (27.72) | 25.82 | (39.67) |
Beginning Cash |
100.50 | 317.20 | 86.80 | 112.80 | 588.40 | 9.20 | 3.20 | 30.91 | 5.09 | 44.76 |
Ending Cash |
142.90 | 100.50 | 317.20 | 86.80 | 112.80 | 588.40 | 9.20 | 3.19 | 30.91 | 5.09 |
Stock Based Compensation |
44.00 | 88.20 | 71.60 | 75.50 | 57.10 | 30.20 | 20.10 | 11.63 | 0.25 | 0.53 |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash/Marketcap |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Assets Liabilities Change (Total) |
(233.70) | (140.60) | (44.40) | (82.60) | 678.30 | (6.00) | 7.10 | 12.57 | 28.21 | (5.56) |
Investments Change (Net) |
409.50 | 36.40 | 206.40 | 249.60 | (1,308.90) | 170.70 | (86.80) | (176.83) | 21.88 | (19.81) |
Issuance/Purchase of Shares |
(91.20) | 8.30 | 391.70 | 4.70 | 283.20 | 532.30 | 140.50 | 169.66 | — | — |
| Other line items | ||||||||||
Revenue per Employee |
1.07 | 0.61 | 0.18 | 0.32 | 0.19 | 0.14 | 0.32 | 0.17 | 0.11 | 0.00 |